BALAXI PHARMACEUTICALS
|
|
BOM :      NSE : BALAXI     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Aug 30,2024 |
Price(EOD): ₹ 107.61
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Trading |
MCap: ₹ 594.01 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
BALAXI PHARMACEUTICALS | 0.5% | -11% | 14.8% |
ADANI ENTERPRISES | -1.6% | -4.7% | 21.1% |
REDINGTON | -0.1% | -4.7% | 28.7% |
HONASA CONSUMER | -0.3% | 9% | NA |
MMTC | 0.1% | -9.3% | 144.4% |
MSTC | -0.2% | -12.2% | 110.3% |
FUNDAMENTAL ANALYSIS OF BALAXI PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF BALAXI PHARMACEUTICALS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
13.08
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 45.44 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 3.01
P/B Calculated based on Book Value of Rs 197.59 Cr
[Latest Year - Mar2024 - Consolidated Results ] 2.47
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 240.96 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
100% 87% 87% |
SHARE PRICE MOMENTUM OF BALAXI PHARMACEUTICALS
BALAXI PHARMACEUTICALS vs SENSEX
DEBT OF BALAXI PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.12 0.13 0.03 0.09 |
0.09 0.07 0.03 0.06 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF BALAXI PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF BALAXI PHARMACEUTICALS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
9.68% -25.11% -35.84% -40.74% |
-0.5% 14.1% 118.71% 115.67% |
QtrlyTrend |
0 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
BALAXI PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about BALAXI PHARMACEUTICALS
Is BALAXI PHARMACEUTICALS good for long term investment?
As on Aug 30,2024, the Fundamentals of BALAXI PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of BALAXI PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is BALAXI PHARMACEUTICALS UnderValued or OverValued?
As on Aug 30,2024, BALAXI PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of BALAXI PHARMACEUTICALS ?
As on Aug 30,2024, the Intrinsic Value of BALAXI PHARMACEUTICALS is Rs. 57.58 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 53.79
Fair Value [Median EV / Sales Model] : Rs. 57.58
Fair Value [Median Price / Sales Model] : Rs. 57.64
Estimated Median Fair Value of BALAXI PHARMACEUTICALS : Rs. 57.58
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is BALAXI PHARMACEUTICALS trading at a Premium or Discount?
As on Aug 30,2024, BALAXI PHARMACEUTICALS is trading at a Premium of 87% based on the estimates of Median Intrinsic Value!ADANI ENTERPRISES LTD vs REDINGTON LTD vs HONASA CONSUMER LTD
MMTC LTD vs MSTC LTD vs LLOYDS ENTERPRISES LTD